期刊
GENOME BIOLOGY
卷 22, 期 1, 页码 -出版社
BMC
DOI: 10.1186/s13059-021-02357-4
关键词
-
资金
- Australian NHMRC Investigator Grant [GNT1176574]
- CSL Centenary Fellowship
- NHMRC [GNT1173711]
- Mater Foundation
Endogenous retroviruses (ERVs) are emerging as promising therapeutic targets in cancer, coordinating gene expression networks and promoting interferon responses. Despite being associated with cancer, autoimmune, and neurodegenerative diseases, harnessing ERV-mediated inflammation may sensitize tumors to immunotherapy.
Endogenous retroviruses (ERVs) are emerging as promising therapeutic targets in cancer. As remnants of ancient retroviral infections, ERV-derived regulatory elements coordinate expression from gene networks, including those underpinning embryogenesis and immune cell function. ERV activation can promote an interferon response, a phenomenon termed viral mimicry. Although ERV expression is associated with cancer, and provisionally with autoimmune and neurodegenerative diseases, ERV-mediated inflammation is being explored as a way to sensitize tumors to immunotherapy. Here we review ERV co-option in development and innate immunity, the aberrant contribution of ERVs to tumorigenesis, and the wider biomedical potential of therapies directed at ERVs.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据